UB Paderborn / Katalog / Suche / in CDI

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Gastroenterology (New York, N.Y. 1943), 2010-07, Vol.139 (1), p.120-129.e18

2010

Volltextzugriff (PDF)

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

The New England journal of medicine, 2013-05, Vol.368 (20), p.1878-1887

2013

Volltextzugriff (PDF)

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

The New England journal of medicine, 2009-08, Vol.361 (6), p.580-593

2009

Volltextzugriff (PDF)

Increased cancer rates in patients with chronic hepatitis C

Liver international, 2020-03, Vol.40 (3), p.685-693

2020

Volltextzugriff (PDF)

Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California

The American journal of managed care, 2023-10, Vol.29 (10), p.e299-e306

Nyberg, Lisa M

2023

Volltextzugriff (PDF)

Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT

BMC gastroenterology, 2020-10, Vol.20 (1), p.362-11, Article 362

2020

Volltextzugriff (PDF)

Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

Journal of hepatology, 2013-03, Vol.58 (3), p.479-487

2013

Volltextzugriff (PDF)

The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States

Hepatology communications, 2021-01, Vol.5 (1), p.83-96

2021

Volltextzugriff (PDF)

Sclerosing mesenteritis and mesenteric panniculitis - clinical experience and radiological features

BMC gastroenterology, 2017-06, Vol.17 (1), p.75-75, Article 75

2017

Volltextzugriff (PDF)

809 The Natural History of Chronic Hepatitis C. an Updated Look At the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-998-S-998

2015

Volltextzugriff (PDF)

Su1433 Real World Experience in Treating Non-Cirrhotic Patients With Genotype 1 Chronic Hepatitis C using Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir With or Without Ribavirin. A prospective Study in a Large Community Based United States Health Care Delivery System

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1098-S1098

2016

Volltextzugriff (PDF)

232 Cost Per Sustained Virological Response 4 (SVR 4) in Genotype 1 Patients Treated With Sofosbuvir and Ledipasvir With and Without Ribavirin. A Detailed Cost-Mapping Study

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1022-S1022

2016

Volltextzugriff (PDF)

Tu1054 Increased Cancer Rates in Patients With Chronic Hepatitis C: An Analysis of the Cancer Registry in a Large U.S. Health Maintenance Organization

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1098-S-1098

2015

Volltextzugriff (PDF)

Tu1068 The Cost Per Cure of Chronic Hepatitis C (HCV). A Cost Mapping Study of Direct Costs Associated With the Treatment of HCV in a Large U.S. Health Maintenance Organization

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1102-S-1102

2015

Volltextzugriff (PDF)

Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin

Hepatology (Baltimore, Md.), 2008-10, Vol.48 (4), p.1033-1043

2008

Volltextzugriff (PDF)

Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection

The American journal of gastroenterology, 2002-08, Vol.97 (8), p.2040-2045

2002

Volltextzugriff (PDF)

450 Simeprevir/Sofosbuvir Therapy in Hepatitis C (HCV) Infected Patients With Child-Pugh Class B/C Cirrhosis Compared to Matched Untreated and Protease Inhibitor (PI)-Triple Therapy Treated Control

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-94-S-94

2015

Volltextzugriff (PDF)

Sa1083 Association of Low Density Lipoprotein and Sustained Virologic Response in Genotypes 2 and 3 Chronic Hepatitis C Patients Treated With Peginterferon and Ribavirin, a Single Center Study

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-964-S-965

2012

Volltextzugriff (PDF)

450 Simeprevir/Sofosbuvir Therapy in Hepatitis C (HCV) Infected Patients With Child-Pugh Class B/C Cirrhosis Compared to Matched Untreated and Protease Inhibitor (PI)-Triple Therapy Treated Control

Gastrointestinal endoscopy, 2015-05, Vol.81 (5), p.AB151-AB151

2015

Volltextzugriff (PDF)

Su1048 Comorbid Conditions Associated With Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-973-S-974

2014

Volltextzugriff (PDF)

Su1047 Resource Utilization During Hepatitis C Treatment With Boceprevir or Telaprevir-Based Triple Therapy vs Dual Therapy in a Large Health Maintenance Organization

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-973-S-973

2014

Volltextzugriff (PDF)

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

Hepatology (Baltimore, Md.), 2008-10, Vol.48 (4), p.1033

2008

Volltextzugriff (PDF)

The Power of Questioning: Guiding Student Investigations

NSTA Press, 2015

2015

Volltextzugriff (PDF)

The Power of Investigating: Guiding Authentic Assessments

NSTA Press, 2017

2017

Volltextzugriff (PDF)

Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study

Clinical infectious diseases, 2014-04, Vol.58 (7), p.960-969

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Increased cancer rates in patients with chronic hepatitis C

Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California

Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT

Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States

Sclerosing mesenteritis and mesenteric panniculitis - clinical experience and radiological features

809 The Natural History of Chronic Hepatitis C. an Updated Look At the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization

Su1433 Real World Experience in Treating Non-Cirrhotic Patients With Genotype 1 Chronic Hepatitis C using Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir With or Without Ribavirin. A prospective Study in a Large Community Based United States Health Care Delivery System

232 Cost Per Sustained Virological Response 4 (SVR 4) in Genotype 1 Patients Treated With Sofosbuvir and Ledipasvir With and Without Ribavirin. A Detailed Cost-Mapping Study

Tu1054 Increased Cancer Rates in Patients With Chronic Hepatitis C: An Analysis of the Cancer Registry in a Large U.S. Health Maintenance Organization

Tu1068 The Cost Per Cure of Chronic Hepatitis C (HCV). A Cost Mapping Study of Direct Costs Associated With the Treatment of HCV in a Large U.S. Health Maintenance Organization

Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin

Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection

450 Simeprevir/Sofosbuvir Therapy in Hepatitis C (HCV) Infected Patients With Child-Pugh Class B/C Cirrhosis Compared to Matched Untreated and Protease Inhibitor (PI)-Triple Therapy Treated Control

Sa1083 Association of Low Density Lipoprotein and Sustained Virologic Response in Genotypes 2 and 3 Chronic Hepatitis C Patients Treated With Peginterferon and Ribavirin, a Single Center Study

450 Simeprevir/Sofosbuvir Therapy in Hepatitis C (HCV) Infected Patients With Child-Pugh Class B/C Cirrhosis Compared to Matched Untreated and Protease Inhibitor (PI)-Triple Therapy Treated Control

Su1048 Comorbid Conditions Associated With Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization

Su1047 Resource Utilization During Hepatitis C Treatment With Boceprevir or Telaprevir-Based Triple Therapy vs Dual Therapy in a Large Health Maintenance Organization

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

The Power of Questioning: Guiding Student Investigations

The Power of Investigating: Guiding Authentic Assessments

Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study

Suchergebnisse filtern